Clinicians must feel knowledgeable and masterful in incorporating lifestyle and integrative therapies targeting nutrition, stress reduction, normalization of sleep, aerobic and mindful exercise, and meaningful activities that add joy and life to years, and not just years to life.
Here are highlights from some of the year’s top features in Psychiatric Times from throughout 2023.
In this CME, learn more about the pathophysiology of HIV-associated neurocognitive disorder and to review the research and various tools used to aid in the diagnosis.
Here are some updates from the world of psychiatry throughout the month of November.
What is new in research on psychedelics?
From neurological abnormalities in first-episode psychosis to psychiatric boarding in emergency departments, here are highlights from the week in Psychiatric Times.
What is new in research on dementia?
New positive data for brexpiprazole, the first and only treatment approved to treat agitation associated with dementia due to Alzheimer disease.
Don't miss the the 2023 Psychiatric Times World CME conference, where our Editor in Chief will present on the 14 different types of dementia!
What is new in research on sleep?
The drug’s developer announced that the FDA has made 2 clarifying revisions.
What is new in research on psychiatric care for Latinx patient populations?
What is new in research on attention-deficit/hyperactivity disorder?
From a look at adolescent substance use to special challenges in treating borderline personality disorder during the perinatal period, here are highlights from the week in Psychiatric Times.
![“The described effects of ACD856 may improve cognition, increase resilience, and promote neurorestorative processes, thereby leading to a healthier brain in patients with [Alzheimer disease].”](https://cdn.sanity.io/images/0vv8moc6/psychtimes/bdc70454947152c592c8b15d4271e2ea649256ea-10500x4750.jpg?w=350&fit=crop&auto=format)
“The described effects of ACD856 may improve cognition, increase resilience, and promote neurorestorative processes, thereby leading to a healthier brain in patients with [Alzheimer disease].”
Trial results underscore the importance of early diagnosis and treatment in patients with Alzheimer disease.
"There is clearly a large unmet need not only to improve our treatment of AD, but to provide treatment options for all the dementias."
From the FDA traditional approval of Leqembi to an examination of how we can improve mental health care for women of color, here are highlights from the week in Psychiatric Times.
Announcement follows the FDA’s accelerated approval and unanimous endorsement of the drug earlier this year.
From substance use among adolescents and young adults to managing behavioral and psychological symptoms of dementia, here are highlights from the week in Psychiatric Times.
Recognition is the first and most important step to treating behavioral and psychological symptoms of dementia.
From the relationship between social media and self-diagnosis to the FDA approval of the first treatment for agitation associated with Alzheimer disease dementia, here are highlights from the week in Psychiatric Times.
Brexpiprazole has been approved by the US Food and Drug Administration for the treatment of agitation associated with Alzheimer disease dementia.
From connections between bvFTD and primary psychiatric disorders to the impact of posttraumatic neuroendocrine dysfunction on recovery, here are highlights from the week in Psychiatric Times.
In this CME, learn more about frontotemporal lobar degeneration and the several overlapping syndromes that it encompasses, as well as how to distinguish behavioral variant frontotemporal lobar degeneration from other psychiatric disorders.
